期刊文献+

肝豆状核变性患者依从性的药学服务研究

Pharmaceutical Care Study on Compliance of Patients with Wilson’s Disease
原文传递
导出
摘要 目的:探讨药学服务对肝豆状核变性患者生活方式与用药依从性的影响。方法:选取2018年1月~2018年12月某院神经内科住院治疗的74例肝豆状核变性患者,药师进行药学干预、随访、问卷调查,评价患者接受药学服务前后生活方式和用药依从性改善情况。结果:药学服务前后患者在用药依从性、合理饮食依从性、不良反应发生率存在显著性差异(P<0.05)。结论:药学服务有利于提高肝豆状核变性患者对合理饮食的依从性和用药依从性,减少不良反应发生。 Objective: To explore the influence of pharmaceutical services on the life quality and compliance of patients with Wilson’s disease. MMeetthh-ods: A total of 74 patients with Wilson’s disease who were hospitalized in department of neurology of a hospital from January 2018 to December2018 were selected. Pharmacists conducted questionnaire survey on pharmaceutical intervention to evaluate the improvement of patients’ lifestyle and medication compliance before and after receiving pharmaceutical services. Results: There was a significant difference in the incidence of adverse reactions, medication compliance and reasonable diet compliance before and after pharmaceutical care(P<0.05). Conclusion: pharmaceutical services is beneficial to improve the compliance with diet and medication, can reduce adverse reactions.
作者 洪燕萍 赖莎 刘爱群 黄叶青 HONG Yan-ping;LAI Sha;LIU Ai-qun;HUANG Ye-qing(The First Affiliated Hospital of Guangdong Pharmaceutical University,Guangzhou,Guangdong 510080)
出处 《按摩与康复医学》 2019年第23期55-57,共3页 Chinese Manipulation and Rehabilitation Medicine
关键词 肝豆状核变性 药学服务 治疗依从性 生活方式 hepatolenticular degeneration/Wilson’s disease pharmaceutical service medication compliance lifestyle
  • 相关文献

参考文献4

二级参考文献32

  • 1吴舒梅,胡文彬,杨任民.二巯丙磺钠的过敏反应及其治疗方法[J].安徽中医学院学报,2006,25(6):45-47. 被引量:11
  • 2陈嵘,梁秀龄,刘焯霖,陈彪,张影如.肝豆状核变性离体培养细胞内锌代谢的综合研究[J].脑与神经疾病杂志,1997,5(1):23-25. 被引量:2
  • 3Brewer GJ, Yuzbasiyan-Gurkan V. Wilson disease[ J]. Medicine (Baltimore) , 1992, 71 (3) :139-164.
  • 4Brewer G J, Fink JK, Hedera P. Diagnosis and treatment of Wilson disease [ J ]. Semin Neurol, 1999, 19 (3) :261-270.
  • 5Brewer GJ, Askari FK. Wilson disease: clinical management and therapy[J]. J Hepatnl, 2005, 42(Snppl 1 ):s13-21.
  • 6Merle U, Schaefer M, Ferenci P, Stremmel W. Clinical presentation, diagnosis and long-term outcome of Wilson's disease:a cohort study[J]. Gut, 2007, 56(1):115-120.
  • 7Young AB, Shoulson I, Penney JB, Starosta-Rubinstein S, Gomez F, Travers H, et al. Huntington's disease in Venezuela: neurologie features and functional decline [ J ]. Neurology, 1986, 36(3) :244.
  • 8Brewer GJ, Dick RD, Yuzbasiyan-Gurkan V, Tankanow R, Young AB, Kluin KJ. Initial therapy of patients with Wilson's disease with tetrathiomolybdate[ J]. Arch Neurol, 1991,48(1 ):42-47.
  • 9Yuzbasiyan-Gurkan V, Grider A, Nostrant T, Cousins R J, Brewer GJ. Treatment of Wilson's disease with zinc: X. Intestinal metallothinnein induction[J]. J Lab Clin Med, 1992, 120(3):380- 386.
  • 10Hoogenraad TU. Paradigm shift in treatment of Wilson's disease: zinc therapy now treatment of choice[J]. Brain Dev, 2006, 28 (3) :141-146.

共引文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部